Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2014; 20(29): 10212-10216
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10212
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10212
E2F transcription factors and digestive system malignancies: How much do we know?
Konstantinos Evangelou, Sophia Havaki, Athanassios Kotsinas, Laboratory Histology-Embryology, Medical School, National and Kapodistrian University of Athens, 11527 Goudi, Athens, Greece
Author contributions: Evangelou K and Kotsinas A wrote the manuscript; Havaki S performed literature search; Kotsinas A designed the study.
Correspondence to: Athanassios Kotsinas, BSc, PhD, Laboratory Histology-Embryology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, 11527 Goudi, Athens, Greece. akotsin@med.uoa.gr
Telephone: +30-210-7462420 Fax: +30-210-7462340
Received: July 21, 2013
Revised: February 22, 2014
Accepted: April 15, 2014
Published online: August 7, 2014
Processing time: 381 Days and 12.3 Hours
Revised: February 22, 2014
Accepted: April 15, 2014
Published online: August 7, 2014
Processing time: 381 Days and 12.3 Hours
Core Tip
Core tip: The roles of the E2F transcription factors can vary significantly in malignancies of the digestive system, often dictating different outcomes in separate compartments of the gastrointestinal tract. Knowledge of the molecular status of the regulatory networks that E2Fs participate in is imperative to define their role. Therefore the use of proper molecular analysis to investigate these networks, complemented also by functional analysis in cellular and animal models, is essential. All in all, such an approach can define chronologically and provide a wider and more accurate view on the exact roles that E2Fs may exhibit in the development of specific digestive system malignancies.